Overview

Affinity Biopharma is a global, clinical stage biopharmaceutical company focused on advancing innovative technology and first-in-class anti-tumor treatment. We have established Tumor MicroEnvironment Activated (TMEA) platform technology including TMEA-SMDC, TMEAbody®, TMEAkine® and TMEA-ICE® platforms, which allow selective unleash of the drug in the tumor microenvironment, reducing “On target, off tumor toxicity” and dramatically improving the therapeutic index. Affinity’s proprietary TMEA platform® could be broadly applied to therapeutic small molecules, cytokines, antibodies, fusion proteins, and ADC.